- Home
- ZKH vs AUTL Comparison
ZKH vs AUTL Comparison
Compare ZKH & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZKH | AUTL |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.8M | 431.2M |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ZKH | AUTL |
|---|---|---|
| Price | $3.14 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 94.2K | ★ 1.8M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $9.02 | $84.74 |
| Revenue Next Year | $10.41 | $65.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $2.20 | $1.15 |
| 52 Week High | $3.90 | $2.70 |
Technical Indicators
Market Signals| Indicator | ZKH | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 62.77 |
| Support Level | $3.08 | $1.23 |
| Resistance Level | $3.54 | $1.69 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 75.68 | 86.34 |
Price Performance
Historical ComparisonAbout ZKH ZKH Group Limited
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.